{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:32:29Z","timestamp":1793892749798,"version":"4.8.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s13760-026-03165-y","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T05:43:09Z","timestamp":1786167789000},"page":"1973-1985","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Kinetic and inhibitory profiling of serum MMP-9 in acute spinal cord injury: neurochemical links to injury severity and neuroinflammation"],"prefix":"10.1007","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5155-2184","authenticated-orcid":false,"given":"Mustafa","family":"Alburhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0480-963X","authenticated-orcid":false,"given":"Omar Khalid","family":"Suhail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7291-4672","authenticated-orcid":false,"given":"Alaa Haleem","family":"Imran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9868-9720","authenticated-orcid":false,"given":"Mustafa Mohammed","family":"Fadhil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"key":"3165_CR1","doi-asserted-by":"publisher","first-page":"e1028","DOI":"10.1016\/j.wneu.2018.10.206","volume":"122","author":"M de Mello Rieder","year":"2019","unstructured":"de Mello Rieder M, Oses JP, Kutchak FM, Sartor M, Cecchini A, Rodolphi MS, Portela LV (2019) Serum biomarkers and clinical outcomes in traumatic spinal cord injury: prospective cohort study. World Neurosurg 122:e1028\u2013e1036. https:\/\/doi.org\/10.1016\/j.wneu.2018.10.206","journal-title":"World Neurosurg"},{"issue":"5","key":"3165_CR2","doi-asserted-by":"publisher","first-page":"100227","DOI":"10.1016\/j.jnrt.2025.100227","volume":"13","author":"Z Liu","year":"2025","unstructured":"Liu Z, Gao H, Man Y, Zhang X, Chen L, Yang M, Li J (2025) Serum biomarkers in the diagnosis and prognosis of traumatic spinal cord injury: A systematic review and meta-analysis. J Neurorestoratology 13(5):100227. https:\/\/doi.org\/10.1016\/j.jnrt.2025.100227","journal-title":"J Neurorestoratology"},{"key":"3165_CR3","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.ebiom.2019.03.003","volume":"41","author":"K Kijima","year":"2019","unstructured":"Kijima K, Kubota K, Hara M, Kobayakawa K, Yokota K, Saito T, Okada S (2019) The acute phase serum zinc concentration is a reliable biomarker for predicting the functional outcome after spinal cord injury. EBioMedicine 41:659\u2013669. https:\/\/doi.org\/10.1016\/j.ebiom.2019.03.003","journal-title":"EBioMedicine"},{"key":"3165_CR4","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3389\/fneur.2019.00282","volume":"10","author":"A Alizadeh","year":"2019","unstructured":"Alizadeh A, Dyck SM, Karimi-Abdolrezaee S (2019) Traumatic spinal cord injury: an overview of pathophysiology, models and acute injury mechanisms. Front Neurol 10:282. https:\/\/doi.org\/10.3389\/fneur.2019.00282","journal-title":"Front Neurol"},{"issue":"20","key":"3165_CR5","doi-asserted-by":"publisher","first-page":"7533","DOI":"10.3390\/ijms21207533","volume":"21","author":"A Anjum","year":"2020","unstructured":"Anjum A, Yazid MDI, Fauzi Daud M, Idris J, Ng AMH, Naicker S, Lokanathan A, Y (2020) Spinal cord injury: pathophysiology, multimolecular interactions, and underlying recovery mechanisms. Int J Mol Sci 21(20):7533. https:\/\/doi.org\/10.3390\/ijms21207533","journal-title":"Int J Mol Sci"},{"issue":"11","key":"3165_CR6","doi-asserted-by":"publisher","first-page":"10797","DOI":"10.1007\/s11033-022-07762-x","volume":"49","author":"P Turczyn","year":"2022","unstructured":"Turczyn P, Wojdasiewicz P, Poniatowski \u0141A, Purrahman D, Ma\u015bli\u0144ska M, \u017burek G, Szukiewicz D (2022) Omega-3 fatty acids in the treatment of spinal cord injury: untapped potential for therapeutic intervention? Mol Biol Rep 49(11):10797\u201310809. https:\/\/doi.org\/10.1007\/s11033-022-07762-x","journal-title":"Mol Biol Rep"},{"issue":"4","key":"3165_CR7","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.3390\/ijms25042117","volume":"25","author":"P Wojdasiewicz","year":"2024","unstructured":"Wojdasiewicz P, Turczyn P, Lach-Gruba A, Poniatowski \u0141A, Purrahman D, Mahmoudian-Sani MR, Szukiewicz D (2024) The role of rosavin in the pathophysiology of bone metabolism. Int J Mol Sci 25(4):2117. https:\/\/doi.org\/10.3390\/ijms25042117","journal-title":"Int J Mol Sci"},{"issue":"3","key":"3165_CR8","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/sj.sc.3102008","volume":"45","author":"JD Steeves","year":"2007","unstructured":"Steeves JD, Lammertse D, Curt A, Fawcett JW, Tuszynski MH, Ditunno JF, Privat A (2007) Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: clinical trial outcome measures. Spinal Cord 45(3):206\u2013221. https:\/\/doi.org\/10.1038\/sj.sc.3102008","journal-title":"Spinal Cord"},{"issue":"2","key":"3165_CR9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/1545968319899920","volume":"34","author":"I Leister","year":"2020","unstructured":"Leister I, Haider T, Mattiassich G, Kramer JL, Linde LD, Pajalic A, Aigner L (2020) Biomarkers in traumatic spinal cord injury\u2014technical and clinical considerations: a systematic review. Neurorehabilit Neural Repair 34(2):95\u2013110. https:\/\/doi.org\/10.1177\/1545968319899920","journal-title":"Neurorehabilit Neural Repair"},{"issue":"17","key":"3165_CR10","doi-asserted-by":"publisher","first-page":"7526","DOI":"10.1523\/JNEUROSCI.22-17-07526.2002","volume":"22","author":"LJ Noble","year":"2002","unstructured":"Noble LJ, Donovan F, Igarashi T, Goussev S, Werb Z (2002) Matrix metalloproteinases limit functional recovery after spinal cord injury by modulation of early vascular events. J Neurosci 22(17):7526\u20137535. https:\/\/doi.org\/10.1523\/JNEUROSCI.22-17-07526.2002","journal-title":"J Neurosci"},{"issue":"2","key":"3165_CR11","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s13311-011-0038-0","volume":"8","author":"H Zhang","year":"2011","unstructured":"Zhang H, Chang M, Hansen CN, Basso DM, Noble-Haeusslein LJ (2011) Role of matrix metalloproteinases and therapeutic benefits of their inhibition in spinal cord injury. Neurotherapeutics 8(2):206\u2013220. https:\/\/doi.org\/10.1007\/s13311-011-0038-0","journal-title":"Neurotherapeutics"},{"issue":"3","key":"3165_CR12","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s12265-018-9789-x","volume":"11","author":"L Lahdentausta","year":"2018","unstructured":"Lahdentausta L, Leskel\u00e4 J, Winkelmann A, Tervahartiala T, Sorsa T, Pesonen E, Pussinen PJ (2018) Serum MMP-9 diagnostics, prognostics, and activation in acute coronary syndrome and its recurrence. J Cardiovasc Transl Res 11(3):210\u2013220. https:\/\/doi.org\/10.1007\/s12265-018-9789-x","journal-title":"J Cardiovasc Transl Res"},{"key":"3165_CR13","doi-asserted-by":"publisher","first-page":"199020","DOI":"10.1016\/j.virusres.2022.199020","volume":"324","author":"A Fortova","year":"2023","unstructured":"Fortova A, H\u00f6nig V, Salat J, Palus M, Pychova M, Krbkova L, Ruzek D (2023) Serum matrix metalloproteinase-9 (MMP-9) as a biomarker in paediatric and adult tick-borne encephalitis patients. Virus Res 324:199020. https:\/\/doi.org\/10.1016\/j.virusres.2022.199020","journal-title":"Virus Res"},{"key":"3165_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jocn.2022.09.002","volume":"105","author":"M Pu","year":"2022","unstructured":"Pu M, You Y, Wang X (2022) Predictive value of serum matrix metalloproteinase 9 combined with tissue inhibitor of metalloproteinase 1 for post-stroke cognitive impairment. J Clin Neurosci 105:103\u2013108. https:\/\/doi.org\/10.1016\/j.jocn.2022.09.002","journal-title":"J Clin Neurosci"},{"issue":"11","key":"3165_CR15","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.3390\/pharmaceutics17111425","volume":"17","author":"M Wolosowicz","year":"2025","unstructured":"Wolosowicz M, Prokopiuk S, Kaminski TW (2025) Matrix Metalloproteinase-9 (MMP-9) as a Therapeutic Target: Insights into Molecular Pathways and Clinical Applications. Pharmaceutics 17(11):1425. https:\/\/doi.org\/10.3390\/pharmaceutics17111425","journal-title":"Pharmaceutics"},{"issue":"9","key":"3165_CR16","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1111\/jnc.15976","volume":"168","author":"KT Kaczmarek","year":"2024","unstructured":"Kaczmarek KT, Protokowicz K, Kaczmarek L (2024) Matrix metalloproteinase-9: A magic drug target in neuropsychiatry? J Neurochem 168(9):1842\u20131853. https:\/\/doi.org\/10.1111\/jnc.15976","journal-title":"J Neurochem"},{"issue":"1","key":"3165_CR17","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s12035-013-8538-z","volume":"49","author":"M Chaturvedi","year":"2014","unstructured":"Chaturvedi M, Kaczmarek L (2014) Mmp-9 inhibition: a therapeutic strategy in ischemic stroke. Mol Neurobiol 49(1):563\u2013573. https:\/\/doi.org\/10.1007\/s12035-013-8538-z","journal-title":"Mol Neurobiol"},{"issue":"15","key":"3165_CR18","doi-asserted-by":"publisher","first-page":"12133","DOI":"10.3390\/ijms241512133","volume":"24","author":"ZA Rashid","year":"2023","unstructured":"Rashid ZA, Bardaweel SK (2023) Novel matrix metalloproteinase-9 (MMP-9) inhibitors in cancer treatment. Int J Mol Sci 24(15):12133. https:\/\/doi.org\/10.3390\/ijms241512133","journal-title":"Int J Mol Sci"},{"issue":"12","key":"3165_CR19","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/nrd4390","volume":"13","author":"RE Vandenbroucke","year":"2014","unstructured":"Vandenbroucke RE, Libert C (2014) Is there new hope for therapeutic matrix metalloproteinase inhibition? Nat Rev Drug Discovery 13(12):904\u2013927. https:\/\/doi.org\/10.1038\/nrd4390","journal-title":"Nat Rev Drug Discovery"},{"key":"3165_CR20","unstructured":"Merck\/Sigma-Aldrich MMP-9 Inhibitor I, Calbiochem\u00ae, Cat. 444278-M. Product information: IC50 5 nM for MMP-9; higher-concentration inhibition of MMP-1 and MMP-13. https:\/\/www.sigmaaldrich.com\/IQ\/en\/product\/mm\/444278m"},{"issue":"3","key":"3165_CR21","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1021\/ja01318a036","volume":"56","author":"H Lineweaver","year":"1934","unstructured":"Lineweaver H, Burk D (1934) The determination of enzyme dissociation constants. J Am Chem Soc 56(3):658\u2013666. https:\/\/doi.org\/10.1021\/ja01318a036","journal-title":"J Am Chem Soc"},{"key":"3165_CR22","doi-asserted-by":"publisher","unstructured":"Seibert E, Tracy TS (2014) Fundamentals of enzyme kinetics. Enzyme Kinetics in Drug Metabolism: Fundamentals and Applications, 9\u201322. https:\/\/doi.org\/10.1007\/978-1-62703-758-7_2","DOI":"10.1007\/978-1-62703-758-7_2"},{"issue":"3\u20134","key":"3165_CR23","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.biochi.2005.01.007","volume":"87","author":"C Lombard","year":"2005","unstructured":"Lombard C, Saulnier J, Wallach J (2005) Assays of matrix metalloproteinases (MMPs) activities: a review. Biochimie 87(3\u20134):265\u2013272","journal-title":"Biochimie"},{"key":"3165_CR24","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/978-1-60327-299-5_24","volume-title":"Matrix metalloproteinase protocols","author":"GB Fields","year":"2010","unstructured":"Fields GB (2010) Using fluorogenic peptide substrates to assay matrix metalloproteinases. Matrix metalloproteinase protocols. Humana, Totowa, NJ, pp 393\u2013433. https:\/\/doi.org\/10.1007\/978-1-60327-299-5_24"},{"key":"3165_CR25","unstructured":"Enzo Life Sciences Matrix Metalloproteinase-9 (MMP-9) Fluorometric Drug Discovery Kit, BML-AK411. https:\/\/www.enzo.com\/product\/matrix-metalloproteinase-9-mmp-9-fluorometric-drug-discovery-kit\/"},{"issue":"1","key":"3165_CR26","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/j.1749-6632.1999.tb07681.x","volume":"878","author":"B Beekman","year":"1999","unstructured":"Beekman B, Drijfhout JW, Ronday HK, TeKoppele JM (1999) Fluorogenic MMP activity assay for plasma including MMPs complexed to \u03b12-macroglobulin. Ann N Y Acad Sci 878(1):150\u2013158. https:\/\/doi.org\/10.1111\/j.1749-6632.1999.tb07681.x","journal-title":"Ann N Y Acad Sci"},{"key":"3165_CR27","doi-asserted-by":"publisher","first-page":"112260","DOI":"10.1016\/j.ejmech.2020.112260","volume":"194","author":"S Mondal","year":"2020","unstructured":"Mondal S, Adhikari N, Banerjee S, Amin SA, Jha T (2020) Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview. Eur J Med Chem 194:112260. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112260","journal-title":"Eur J Med Chem"},{"issue":"1","key":"3165_CR28","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4103\/abr.abr_122_21","volume":"12","author":"A Forouzan","year":"2023","unstructured":"Forouzan A, Fahimi MA, Bastan ASI, Delirrooyfard A (2023) Diagnostic competence of creatine kinase BB, in mild traumatic brain injury and its prognostic value. Adv Biomedical Res 12(1):84. https:\/\/journals.lww.com\/adbm\/fulltext\/2023\/03280\/diagnostic_competence_of_creatine_kinase_bb,_in.84.aspx","journal-title":"Adv Biomedical Res"},{"issue":"16","key":"3165_CR29","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1016\/S0960-894X(01)00419-X","volume":"11","author":"JI Levin","year":"2001","unstructured":"Levin JI, Chen J, Du M, Hogan M, Kincaid S, Nelson FC, Skotnicki JS (2001) The discovery of anthranilic acid-Based MMP inhibitors. Part 2: SAR of the 5-position and P11 groups. Bioorg Med Chem Lett 11(16):2189\u20132192. https:\/\/doi.org\/10.1016\/S0960-894X(01)00419-X","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"3165_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41394-024-00636-3","volume":"10","author":"S Shool","year":"2024","unstructured":"Shool S, Rahmani S, Habibi MA, Piri SM, Lotfinia M, Jashnani D, Asaadi S (2024) Acute spinal cord injury serum biomarkers in human and rat: a scoping systematic review. Spinal Cord Ser Cases 10(1):21. https:\/\/doi.org\/10.1038\/s41394-024-00636-3","journal-title":"Spinal Cord Ser Cases"},{"issue":"9\u201310","key":"3165_CR31","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1177\/08977151251401222","volume":"43","author":"EA Schaeffer","year":"2026","unstructured":"Schaeffer EA, Levy AS, Errante EL, Costello MC, Smartz T, Levi AD, Papa L (2026) Biofluid Biomarkers of Acute Traumatic Spinal Cord Injury: A Systematic Review. J Neurotrauma 43(9\u201310):689\u2013703. https:\/\/doi.org\/10.1177\/08977151251401222","journal-title":"J Neurotrauma"},{"key":"3165_CR32","doi-asserted-by":"publisher","unstructured":"Azad TD, Ran KR, Materi JD, Raj D, Al-Khindi T, Gabbita S, Bettegowda C (2025) A multi-analyte blood test for acute spinal cord injury. J Clin Investig 135(5). https:\/\/doi.org\/10.1172\/JCI185463","DOI":"10.1172\/JCI185463"},{"issue":"24","key":"3165_CR33","doi-asserted-by":"publisher","first-page":"13460","DOI":"10.3390\/ijms252413460","volume":"25","author":"M Nakazaki","year":"2024","unstructured":"Nakazaki M, Yokoyama T, Lankford KL, Hirota R, Kocsis JD, Honmou O (2024) Mesenchymal stem cells and their extracellular vesicles: therapeutic mechanisms for blood\u2013spinal cord barrier repair following spinal cord injury. Int J Mol Sci 25(24):13460. https:\/\/doi.org\/10.3390\/ijms252413460","journal-title":"Int J Mol Sci"},{"issue":"6","key":"3165_CR34","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1021\/acs.biochem.5c00765","volume":"65","author":"I Marko","year":"2026","unstructured":"Marko I, Johnson KA (2026) Enzyme Kinetic Analysis for the 21st Century. Biochemistry 65(6):637\u2013648. https:\/\/doi.org\/10.1021\/acs.biochem.5c00765","journal-title":"Biochemistry"},{"key":"3165_CR35","doi-asserted-by":"publisher","first-page":"123546","DOI":"10.1016\/j.wneu.2024.12.005","volume":"194","author":"E Tao","year":"2025","unstructured":"Tao E, Liu Z, Liu Y, Wang C, Huang G, Xu C, Ding Z (2025) Serum C-Reactive Protein-to-Albumin Ratio as a Clinical Risk Factor for Traumatic Spinal Cord Injury. World Neurosurg 194:123546. https:\/\/doi.org\/10.1016\/j.wneu.2024.12.005","journal-title":"World Neurosurg"},{"issue":"1","key":"3165_CR36","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1186\/s12891-024-08038-0","volume":"25","author":"Z Ding","year":"2024","unstructured":"Ding Z, Zhou W, Wang D, Li L, Wang C, Wang C (2024) MRI variables and peripheral inflammatory response biomarkers predict severity and prognosis in patients with acute cervical traumatic spinal cord injury. BMC Musculoskelet Disord 25(1):900. https:\/\/doi.org\/10.1186\/s12891-024-08038-0","journal-title":"BMC Musculoskelet Disord"},{"issue":"10","key":"3165_CR37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3389\/fneur.2019.00027","volume":"29","author":"AA Albayar","year":"2019","unstructured":"Albayar AA, Roche A, Swiatkowski P, Antar S, Ouda N, Emara E, Awad BI (2019) Biomarkers in spinal cord injury: prognostic insights and future potentials. Front Neurol 29(10):27. https:\/\/doi.org\/10.3389\/fneur.2019.00027","journal-title":"Front Neurol"},{"issue":"43","key":"3165_CR38","doi-asserted-by":"publisher","first-page":"17963","DOI":"10.1074\/jbc.M117.806075","volume":"292","author":"RH Scannevin","year":"2017","unstructured":"Scannevin RH, Alexander R, Haarlander TM, Burke SL, Singer M, Huo C, Rhodes KJ (2017) Discovery of a highly selective chemical inhibitor of matrix metalloproteinase-9 (MMP-9) that allosterically inhibits zymogen activation. J Biol Chem 292(43):17963\u201317974. https:\/\/doi.org\/10.1074\/jbc.M117.806075","journal-title":"J Biol Chem"},{"key":"3165_CR39","doi-asserted-by":"publisher","unstructured":"Brumann, M., Kusmenkov, T., Ney, L., Kanz, K. G., Leidel, B. A., Biberthaler, P.,\u2026 Bogner, V. (2012). Concentration Kinetics of Serum MMP-9 and TIMP\u20101 after Blunt Multiple Injuries in the Early Posttraumatic Period. Mediators of inflammation, 2012(1),435463. https:\/\/doi.org\/10.1155\/2012\/435463","DOI":"10.1155\/2012\/435463"},{"issue":"1","key":"3165_CR40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1023\/B:HREV.0000011395.11179.af","volume":"9","author":"JT Peterson","year":"2004","unstructured":"Peterson JT (2004) Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev 9(1):63\u201379. https:\/\/doi.org\/10.1023\/B:HREV.0000011395.11179.af","journal-title":"Heart Fail Rev"},{"key":"3165_CR41","doi-asserted-by":"publisher","unstructured":"Nagy, B., Sz\u00e9lig, L., Rendeki, S., Loibl, C., R\u00e9zm\u00e1n, B., Lantos, J., \u2026 Csontos, C.(2015). Dynamic changes of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 after burn injury. Journal of critical care, 30(1), 162\u2013166. https:\/\/doi.org\/10.1016\/j.jcrc.2014.07.008","DOI":"10.1016\/j.jcrc.2014.07.008"},{"issue":"24","key":"3165_CR42","doi-asserted-by":"publisher","first-page":"7162","DOI":"10.1111\/febs.15701","volume":"288","author":"W Bassiouni","year":"2021","unstructured":"Bassiouni W, Ali MA, Schulz R (2021) Multifunctional intracellular matrix metalloproteinases: implications in disease. FEBS J 288(24):7162\u20137182. https:\/\/doi.org\/10.1111\/febs.15701","journal-title":"FEBS J"},{"issue":"1","key":"3165_CR43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11010-016-2805-z","volume":"422","author":"F Darabi","year":"2016","unstructured":"Darabi F, Aghaei M, Movahedian A, Pourmoghadas A, Sarrafzadegan N (2016) The role of serum levels of microRNA-21 and matrix metalloproteinase-9 in patients with acute coronary syndrome. Mol Cell Biochem 422(1):51\u201360. https:\/\/doi.org\/10.1007\/s11010-016-2805-z","journal-title":"Mol Cell Biochem"},{"issue":"8","key":"3165_CR44","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.jocn.2015.02.021","volume":"22","author":"GD G\u00fcltekin","year":"2015","unstructured":"G\u00fcltekin GD, \u00c7abuk B, Vural \u00c7, Ceylan S (2015) Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-2: Prognostic biological markers in invasive prolactinomas. J Clin Neurosci 22(8):1282\u20131287. https:\/\/doi.org\/10.1016\/j.jocn.2015.02.021","journal-title":"J Clin Neurosci"},{"issue":"8","key":"3165_CR45","doi-asserted-by":"publisher","first-page":"6436","DOI":"10.1007\/s12035-017-0858-y","volume":"55","author":"LF Rodrigues","year":"2018","unstructured":"Rodrigues LF, Moura-Neto V, e Spohr TCLDS (2018) Biomarkers in spinal cord injury: from prognosis to treatment. Mol Neurobiol 55(8):6436\u20136448. https:\/\/doi.org\/10.1007\/s12035-017-0858-y","journal-title":"Mol Neurobiol"},{"issue":"25\u201326","key":"3165_CR46","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.lfs.2013.10.015","volume":"93","author":"J Yang","year":"2013","unstructured":"Yang J, Wang G, Gao C, Shao G, Kang N (2013) Effects of hyperbaric oxygen on MMP-2 and MMP-9 expression and spinal cord edema after spinal cord injury. Life Sci 93(25\u201326):1033\u20131038. https:\/\/doi.org\/10.1016\/j.lfs.2013.10.015","journal-title":"Life Sci"},{"issue":"4","key":"3165_CR47","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1089\/08977150252932433","volume":"19","author":"M Aksenova","year":"2002","unstructured":"Aksenova M, Butterfield DA, Zhang SX, Underwood M, Geddes JW (2002) Increased protein oxidation and decreased creatine kinase BB expression and activity after spinal cord contusion injury. J Neurotrauma 19(4):491\u2013502. https:\/\/doi.org\/10.1089\/08977150252932433","journal-title":"J Neurotrauma"},{"issue":"3","key":"3165_CR48","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1080\/10790268.2002.11753616","volume":"25","author":"Y Szlachcic","year":"2002","unstructured":"Szlachcic Y, Adkins RH, Waters RL, Govindarajan S, Wang J, Yee F, Greenwood J (2002) Incidence and clinical correlates of increased serum creatine kinase levels in persons with spinal cord injury. J Spinal Cord Med 25(3):156\u2013160. https:\/\/doi.org\/10.1080\/10790268.2002.11753616","journal-title":"J Spinal Cord Med"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-026-03165-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-026-03165-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-026-03165-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:51:27Z","timestamp":1793890287000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-026-03165-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,8]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["3165"],"URL":"https:\/\/doi.org\/10.1007\/s13760-026-03165-y","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,8]]},"assertion":[{"value":"2 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involved human participants and was conducted in accordance with the ethical principles of the Declaration of Helsinki and its later amendments or comparable ethical standards. The research protocol, numbered 47\/2026, was reviewed and approved by The Research Committee of the National Centre for Training and Human Development, Iraqi Ministry of Health, following standard procedures.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all individual participants prior to their inclusion in the study. When necessary, written informed consent was obtained from the participants\u2019 guardians.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors affirm that participants provided consent for publication of anonymized data. No identifiable individual data, images, videos, or case-specific details are included in this manuscript.","order":4,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}}]}}